J. Harland

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

R Rampling, G. Cruickshank, Vakis Papanastassiou et al. · Gene Therapy · 2000 · 598 citations

Medicine, Molecular Biology, Oncology +10

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival

Stephen Harrow, Vakis Papanastassiou, J. Harland et al. · Gene Therapy · 2004 · 342 citations

Medicine, Oncology, Surgery +10

The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

Vakis Papanastassiou, R Rampling, Matthew Fraser et al. · Gene Therapy · 2002 · 328 citations

Medicine, Infectious Diseases, Oncology +7

Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence

Alasdair Maclean, M. Ul-Fareed, L. Robertson et al. · Journal of General Virology · 1991 · 254 citations

Life Sciences, Genetics, Infectious Diseases +14

The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino-acid domain conserved in ICP34.5, MyD116, and GADD34

Stuart M. Brown, Alasdair Maclean, E. A. McKie et al. · Journal of Virology · 1997 · 97 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +12